8 completed. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
Follow Sickle Cell Anemia: new trials by email Literature Review of Sickle Cell Anemia trials Research Report on Sickle Cell Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hydroxyurea Optimization Through Precision Study Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Lifespan | 104 | 2019-01-17 | 2025-06-18 |
| Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas Hydroxyurea - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 187 | 2017-07-26 | 2020-02-20 |
| Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa Moderate Dose Hydroxyurea, Low Dose Hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Completed | Vanderbilt University Medical Center | 120 | 2017-01-01 | 2022-01-19 |
| Novel Use Of Hydroxyurea in an African Region With Malaria Hydroxyurea, Placebo - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Completed | Indiana University | 208 | 2014-09-01 | 2018-12-04 |
| A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia L-glutamine, Placebo - Sickle Cell Anemia, Sickle ß0-Thalassemia | Phase 3 | Completed | Emmaus Medical, Inc. | 230 | 2010-05-01 | 2020-08-19 |
| Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia sulfadoxine pyrimethamine - Sickle Cell Anemia, Malaria | Phase 3 | Completed | Makerere University | 220 | 2006-10-01 | 2009-07-02 |
| Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial transfusion therapy - Sickle Cell Anemia, Stroke | Phase 3 | Completed | Washington University School of Medicine | 196 | 2004-12-01 | 2016-02-08 |
| Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease poloxamer 188 - Sickle Cell Anemia | Phase 3 | Completed | Mast Therapeutics, Inc. | 300 | 1997-11-01 | 2012-03-06 |
Anemia, Sickle Cell (8) · Malaria (3) · Stroke (2) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Pain (1) · Rare Diseases (1) · Vaso-Occlusive Crises (1)
Anemia (8) · Anemia, Hemolytic (8) · Anemia, Hemolytic, Congenital (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Hemic and Lymphatic Diseases (8) · Hemoglobinopathies (8) · Genetic Diseases, Inborn (7) · Hematologic Diseases (7) · Infections (3) · Mosquito-Borne Diseases (3) · Parasitic Diseases (3) · Protozoan Infections (3) · Vector Borne Diseases (3) · Brain Diseases (2) · Cardiovascular Diseases (2)
Hydroxyurea (4) · Glutamine (1) · Poloxamer (1) · fanasil, pyrimethamine drug combination (1) · maltodextrin (1)
Indiana University (2) · Emmaus Medical, Inc. (1) · Lifespan (1) · Makerere University (1) · Mast Therapeutics, Inc. (1) · Vanderbilt University Medical Center (1) · Washington University School of Medicine (1)
Uganda (3) · United States (3) · Nigeria (1)
Michael R. DeBaun, MD, MPH (2) · Chandy C John, M.D. (1) · Chandy C. John, M.D. (1) · Christopher Ndugwa, PhD (1) · Deborah Nakiboneka, M.Med (1) · Grace Ndeezi, M.Med (1) · James Tumwine, PhD (1) · Patrick Niss, MD (1) · R. Martin Emanuele (1) · Victoria Nakibuuka, MBChB (1) · Yutaka Niihara, MD, MPH (1)
PMID 21179892, PMID 21523806, PMID 24529619, PMID 25140956, PMID 27339303, PMID 29051184, PMID 30021096, PMID 30952488, PMID 31135090, PMID 32579813, PMID 33246482, PMID 34607344, PMID 38775255, PMID 40765704, PMID 41026975
U01NS042804 (1)